EP1233774A4 - Analogues d'urotensine ii - Google Patents

Analogues d'urotensine ii

Info

Publication number
EP1233774A4
EP1233774A4 EP00980842A EP00980842A EP1233774A4 EP 1233774 A4 EP1233774 A4 EP 1233774A4 EP 00980842 A EP00980842 A EP 00980842A EP 00980842 A EP00980842 A EP 00980842A EP 1233774 A4 EP1233774 A4 EP 1233774A4
Authority
EP
European Patent Office
Prior art keywords
urotensin
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00980842A
Other languages
German (de)
English (en)
Other versions
EP1233774A1 (fr
Inventor
Dashyant Dhanak
Steven D Knight
Gregory L Warren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1233774A1 publication Critical patent/EP1233774A1/fr
Publication of EP1233774A4 publication Critical patent/EP1233774A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
EP00980842A 1999-11-29 2000-11-29 Analogues d'urotensine ii Withdrawn EP1233774A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16814199P 1999-11-29 1999-11-29
US168141P 1999-11-29
PCT/US2000/032408 WO2001037780A2 (fr) 1999-11-29 2000-11-29 Analogues d'urotensine ii

Publications (2)

Publication Number Publication Date
EP1233774A1 EP1233774A1 (fr) 2002-08-28
EP1233774A4 true EP1233774A4 (fr) 2004-06-16

Family

ID=22610297

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00980842A Withdrawn EP1233774A4 (fr) 1999-11-29 2000-11-29 Analogues d'urotensine ii

Country Status (3)

Country Link
EP (1) EP1233774A4 (fr)
JP (1) JP2003527341A (fr)
WO (1) WO2001037780A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL366327A1 (en) * 2000-10-20 2005-01-24 The Administrators Of The Tulane Educational Fund Urotensin-ii agonists and antagonists
AU2003275602A1 (en) * 2002-10-25 2004-05-13 Takeda Pharmaceutical Company Limited Antibody and utilization of the same
ITFI20030238A1 (it) 2003-09-11 2005-03-12 Paolo Grieco Peptidi ciclici antagonisti dell'urotensina-ii
ITFI20070032A1 (it) * 2007-02-09 2008-08-10 Alfredo Budillon Ligandi di natura peptidica e non peptidica del recettore ut dell'urotensina-ii, composizioni farmaceutiche che li contengono e loro uso.
CA2832464A1 (fr) * 2011-05-03 2012-11-08 Institut National De La Recherche Scientifique Nouveaux agonistes et antagonistes du systeme urotensinergique
FR2982488B1 (fr) * 2011-11-10 2013-12-27 Univ Rouen Urotensine ii pour son utilisation dans le traitement et/ou la prevention de pathologies impliquant la motilite gastrique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BEHM D J ET AL: "PHARMACOLOGICAL CHARACTERIZATION OF SB-710411 (CPA-CÄD-CYS-PAL-D-TRP-LYS-VAL-CYSÜ-CPA-AMIDE), A NOVEL PEPTIDIC UROTENSIN-II RECEPTOR ANTAGONIST", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 137, no. 4, October 2002 (2002-10-01), pages 449 - 458, XP001153544, ISSN: 0007-1188 *
CONLON J M ET AL: "ISOLATION AND PRIMARY STRUCTURE OF UROTENSIN II FROM THE BRAIN OF A TETRAPOD, THE FROG RANA RIDIBUNDA", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 188, no. 2, 30 October 1992 (1992-10-30), pages 578 - 583, XP000311226, ISSN: 0006-291X *
COULOUARN Y ET AL: "Cloning of the cDNA encoding the Urotensin II precursor in frog and human reveals intense expression of the Urotensin II gene in motoneurons of the spinal cord", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, no. 26, 22 December 1998 (1998-12-22), pages 15803 - 15808, XP002110994, ISSN: 0027-8424 *
COY D H ET AL: "Novel urotensin II (UII) antagonists point to multiple receptor involvement in UII bioactivity", REGULATORY PEPTIDES, vol. 94, no. 1-3, 25 October 2000 (2000-10-25), 13th International Symposium on Regulatory Peptides;Cairns, Queensland, Australia; October 22-26, 2000, pages 48, XP002267294, ISSN: 0167-0115 *
DOUGLAS S A ET AL: "HUMAN UROTENSIN-II, THE MOST POTENT MAMMALIAN VASOCONSTRICTOR IDENTIFIED TO DATE, AS A THERAPEUTIC TARGET FOR THE MANAGEMENT OF CARDIOVASCULAR DISEASE", TRENDS IN CARDIOVASCULAR MEDICINE, ELSEVIER SCIENCE, NEW YORK, NY, US, vol. 10, no. 6, August 2000 (2000-08-01), pages 229 - 237, XP001153538, ISSN: 1050-1738 *
PERKINS T D J ET AL: "Molecular modelling and design of analogues of the peptide hormone Urotensin II", BIOCHEMICAL SOCIETY TRANSACTIONS, COLCHESTER, ESSEX, GB, vol. 18, no. PART 5, October 1990 (1990-10-01), pages 918 - 919, XP002110993, ISSN: 0300-5127 *

Also Published As

Publication number Publication date
JP2003527341A (ja) 2003-09-16
WO2001037780A2 (fr) 2001-05-31
EP1233774A1 (fr) 2002-08-28
WO2001037780A8 (fr) 2001-11-08

Similar Documents

Publication Publication Date Title
DE60008112D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE60008382D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE50008011D1 (en) Thixotropierungsmittel
DE50002614D1 (en) Sigma-delta-modulator
DE60007505D1 (en) Propargyletherderivate
DE60011809D1 (en) Oxcarbazepinsuspension
DE50009469D1 (en) Common-rail-injektor
DE60012950D1 (en) Polyacetalharzzusammensetzung
DE50010757D1 (en) Stilbenaufheller
PL353372A1 (en) Substituted heterocyclyl-2h-chromenes
EP1233774A4 (fr) Analogues d'urotensine ii
DE50008218D1 (en) Common-rail-injektor
DE60012212D1 (en) Orthotopisches totalkunstherz
DE60004080D1 (en) Centroidintegration
GB9913742D0 (en) Horologe improvement
AU141428S (en) Turnpiece
DE50008219D1 (en) Common-rail-injektor
DE50012739D1 (en) Thermovliesstoff
GB9911456D0 (en) Oligohydroxyl substituted 3-urea-benzofurane-and-pyridofurane-derivatives
EP1233776A4 (fr) Analogues d'urotensine ii cyclique
DE60007846D1 (en) Sterndreieckschalter
PL352101A1 (en) Substituted phenylcyclohexanocarboxyamides
DE60014693D1 (en) O-desmethylvenlafaxin-ether
GB9903377D0 (en) Amphibious-tricycle (amphi-trike)
GB9905498D0 (en) Expression

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 7/06 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040423

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040715